

Institutional Biosafety Committee

Date | time 9/18/2025 10:00 AM / Meeting called to order by:

Dr. Andrew Hayhurst

Meeting adjourned at 10:20 AM

In Attendance by ZOOM

Member	Expertise	Present
Andrew Hayhurst, Ph.D.	Protein engineering, display systems, BoNT, BSL-2, 4 (chair)	Y
Tim Anderson, Ph.D.	Pathogen evolution, malaria & schistosome drug resistances	N
Hsiang Ming (Anthony) Wang, Ph.D.	Director EHS, RO, alternate BSO, BSL-2, 3, 4	N
Marie-Claire Gauduin, Ph.D.	Recombinant virus vectors, NHP, HIV vaccines, retroviruses, BSL-2, 3	N
Trent Peacock, Ph.D.	BSO, ARO, molecular diagnostics, BSL-2, 3, 4 (vice-chair)	Y
Yan Xiang, Ph.D.	Mechanisms of poxvirus pathogenesis, (community member)	N
Felicia Ponce	IACUC Manager	Y
Olena Shtanko, Ph.D.	Molecular virology, viral entry, pathogenesis, BSL-2, 3, 4	Y
Davida Smyth, Ph.D.	Microbial epidemiology & genomics, (community member)	N
Luis Martinez Sobdrido, Ph.D.	Viral reverse genetics, attenuated vaccines, antivirals, BSL-2, 3, 4	N
Diako Ebrahimi, Ph.D.	Viral evolution, HIV, statistical biology	Y
Olga Gonzalez, D.V.M.	Veterinary pathology at ABSL-2, 3, 4, infectious/natural diseases and aging of NHP	Y
Jack Dutton, D.V.M.	Veterinarian, ABSL-2, 3, 4, animal models of infectious disease, countermeasure assessment	Y
Kathy Brasky, V.M.D.	Primary veterinarian, ABSL-2, 3, 4, animal models of infectious disease, countermeasure assessment, diverse NHP biology	N
Jason Bowling, M.D.	Human infectious disease medicine, epidemiology, infection prevention	Y
John Choe, M.D.	Occupational health	N
Greg Ippolito, Ph.D.	Immunology, antibody Repertoires, B-cell biology, vaccines and infectious diseases	Y

Quorum: 9/17 = 52.94 %. For the application with OS in COI (as PI), only 8/17 members were present (no quorum). AW provided comments and conditional approval by email.

Other Individuals in Attendance: Erica Arreola and Winka Le Clec'h – recording the Institutional minutes

Call to order: The IBC Chair called the meeting to order at 10:00 am

Conflicts of Interest: Request was made to members to self-identify if conflicts of interest arise and recuse as necessary.

Approval of Minutes: Minutes from IBC August 2025 meeting approved.

Update on previous business: All revisions required from last meeting were made and approved. BrdU was withdrawn from protocol 25-013 (last month's review), so the application now requires only IACUC approval and no longer IBC consideration.

Discussion: None

New IBC Registrations & Amendments for Review:

PI Name: Vivek Kumbhari

BSCRDC22-010.2– Addition of mRNA/LNP

Lay description, provided by PI: In line with the parent application, the team's goal is to use gene therapy to cure liver diseases. Previously, genes were delivered on plasmids, but with a suboptimal efficiency. Here, the piggyBactransposase transposase will be delivered via mRNA/LNP for rapid synthesis and immediate cassette integration in liver cells. The plasmid–LNP solution will be administered endoscopically.

Agent characteristics: mRNA encoding piggyBactransposase encapsulated within lipid nanoparticle (LNP).

Types of manipulations planned: The transposase–LNP solution will be administered endoscopically to the liver, where the enzyme will be rapidly synthesized to integrate cassettes of interest into the DNA of targeted cells.

Sources of nucleic acids: piggyBacTransposase (originally from the cabbage looper moth).

Nature of sequences: The transposase recognizes sequences flanking the plasmid-borne expression cassette, enabling its excision and integration into homologous chromosomal sites.

Foreign gene(s) expressed: The expressed foreign genes are listed in the parent application (July 2022).

Hosts and vectors to be used: Host: Baboon. Vector: mRNA is the new addition, while the gene remains the same.

Biosafety Level and containment: BSL-2.

PI and lab staff trained: The SNPRC has safely conducted similar studies for years, and the team is experienced in these procedures.

Occupational Health Representative Review (if applicable):

Risk Assessment and Discussion:

Applicable section of guidelines: III-D-4a

The following will require clarification: None.

Motion: **Approval | 9 Approve (AW by email), 0 Against, 0 Abstain**

PI Name: Olena Shtanko

IBC25-013– Addition of macaque blood and tissues

Lay description, provided by PI: The objective is to study Ebola and other filoviruses' replication and effects on the cellular phenotype of Rhesus Macaque cells. With PI approval, blood and tissue samples from animals enrolled in other studies will first be processed in the PI's BSL-2 laboratory, then transferred to the BSL-4.

Agent characteristics: Ebola and other filoviruses.

Types of manipulations planned: Isolation of Rhesus Macaque blood and tissue cells for in vitro infection with Ebola and other filoviruses.

Sources of nucleic acids: No recombinant/synthetic nucleic acids involved

Nature of sequences: NA

Foreign gene(s) expressed: NA

Hosts to be used: Rhesus Macaques.

Biosafety Level and containment: BSL-2 and BSL-4

PI and lab staff trained: The PI's lab has safely processed human blood and tissues for several years.

Occupational Health Representative Review (if applicable):

No additional occupational health requirements were recommended at this time.

Risk Assessment and Discussion:

Applicable section of guidelines: NA

The following will require clarification: None. Discussion included acquiring a bite-and-scratch kit for BSL-2 processing of Rhesus Macaque samples (Herpes B virus), sample transport to the PI lab, staff removal, and adding a biospecimen IACUC request for PI collaborators.

Motion: **Approval | 8 Approve (AW by email), 0 Against, 1 Abstain as COI**

Meeting adjourned at 10:20AM

Next IBC meeting:

10/16/2025 10:00 AM, Zoom